Year archive

IRLAB Therapeutics — 2022 filings

All 23 regulatory filings released by IRLAB Therapeutics (IRLAB) in 2022, sourced directly from the official regulator.

23 Filings

2022 Period

2022 filings (23)

Filing	Released	Lang
Nomination committee in IRLAB appointed ahead of annual general meeting 2023 AGM Information	2022-11-15	English
Valberedningen utsedd inför IRLAB:s årsstämma 2023 Board/Management Information	2022-11-15	Swedish
Interim / Quarterly Report 2022 Interim / Quarterly Report 9M 2022	2022-11-09	Swedish
Interim / Quarterly Report 2022 Interim / Quarterly Report 9M 2022	2022-11-09	English
Interim / Quarterly Report 2022 Interim / Quarterly Report H1 2022	2022-08-24	Swedish
Interim / Quarterly Report 2022 Interim / Quarterly Report Q2 2022	2022-08-24	English
Changed number of shares and votes in IRLAB Therapeutics AB Declaration of Voting Results & Voting Rights Announcements	2022-08-01	English
Förändrat antal aktier och röster i IRLAB Therapeutics AB Share Issue/Capital Change	2022-08-01	Swedish
IRLAB expands Phase IIb/III PD-LIDs study with mesdopetam to support Phase III program and expects completion of enrollment during the summer Regulatory Filings	2022-07-11	English
IRLAB utökar Fas IIb PD-LIDs-studien med mesdopetam för att stödja Fas III-programmet och förväntas slutföra rekrytering till studien under sommaren Regulatory Filings	2022-07-11	Swedish
IRLAB strengthens its management team by appointing Richard Godfrey as new CEO and Nicholas Waters as Executive Vice President and Head of R&D Board/Management Information	2022-06-09	English
IRLAB stärker bolagsledningen genom att utse Richard Godfrey till ny vd och Nicholas Waters till Executive Vice President and Head of R&D Board/Management Information	2022-06-09	Swedish
Report from the Annual General Meeting of IRLAB Therapeutics AB AGM Information	2022-05-11	English
Kommuniké från årsstämma 2022 i IRLAB Therapeutics AB AGM Information	2022-05-11	Swedish
Interim / Quarterly Report 2022 Interim / Quarterly Report Q1 2022	2022-05-11	Swedish
Interim / Quarterly Report 2022 Interim / Quarterly Report Q1 2022	2022-05-11	English
IRLAB acquires know-how connected to the P003 project aimed at an innovative treatment for Parkinson’s disease Regulatory Filings	2022-04-22	English
IRLAB förvärvar know-how kopplad till P003-projektet som är inriktat mot innovativ behandling av Parkinsons sjukdom Share Issue/Capital Change	2022-04-22	Swedish
NOTICE TO ATTEND THE ANNUAL GENERAL MEETING OF AGM Information	2022-04-11	English
KALLELSE TILL ÅRSSTÄMMA I IRLAB THERAPEUTICS AB AGM Information	2022-04-11	Swedish
Annual Report (ESEF) 2021 Annual Report (ESEF) FY 2021	2022-04-08	Swedish
Interim / Quarterly Report 2021 Interim / Quarterly Report FY 2021	2022-02-23	Swedish
Interim / Quarterly Report 2021 Interim / Quarterly Report FY 2021	2022-02-23	English